Back to search results

Study of EIK1004 (IMP1707) for Advanced Solid Tumors

This study is testing a drug called EIK1004 (IMP1707), which is a PARP1 selective inhibitor (a type of drug that targets a specific protein involved in cancer growth). It's for people aged 18 to 89 with advanced solid tumors, specifically recurrent breast cancer, ovarian cancer, metastatic prostate cancer, or pancreatic cancer. You must have certain genetic changes (mutations in homologous recombination repair (HRR) genes) to be eligible. The main goals are to see how safe EIK1004 (IMP1707) is and what dose is best, as well as to look for early signs that it might be effective against cancer. The study is currently recruiting participants.

Study design
This is a Phase 1/Phase 2 study with an estimated 130 participants. It has two parts: dose escalation to find the best dose, and dose optimization to further evaluate safety and effectiveness.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for adverse events for one month after their last dose of EIK1004 (IMP1707).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06907043

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Recruiting
PHASE1Ages 18–89InterventionalTreatment
Eikon Therapeutics
~130 participants
Updated 2025-08-19 on ClinicalTrials.gov
What's tested:EIK1004-001 (IMP1707-001)

At a glance

Recruiting sites
10 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants who experience a Dose-Limiting Toxicity (DLT)
Measured over (Timeframe: up to 28 days)
+1 more outcome measured

Conditions

Advanced Solid Tumors

Explore related trials

Breast CarcinomaMalignant Ovarian NeoplasmPancreatic CarcinomaProstate CarcinomaSolid NeoplasmAHRR Gene

Where it's being run

10 sites across 9 states
Texas2
Colorado1
Florida1
Massachusetts1
Virginia1
Victoria1
Chongqing Municipality1
Shandong1

Study leadership

  • Yawei Zhang, MD · STUDY_DIRECTOR · Eikon Therapeutics

Who to contact

Sunny Chaudry, MS
[email protected]
6319026200
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Untreated CNS metastases (measurable and/or non-measurable) not needing immediate local therapy.
Previously treated CNS metastases

Exclusion

Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of EIK1004 (IMP1707)
Have received prior PARP1 selective inhibitors
Mean resting QTcF \> 470 ms or QTcF \< 340 ms
Infections
Any known predisposition to bleeding
Unable to swallow oral medications OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability
Any untreated brain lesions \> 2.0 cm in size.
Ongoing use of systemic corticosteroids for control of symptoms of CNS metastases \< 7 days prior to the first dose of study treatment or requirement for \> 10 mg prednisone/day.
Any brain lesion requiring immediate local therapy, including (but not limited to) a lesion in an anatomic site where an increase in size or possible treatment-related edema may pose risk to the participant (eg, brain stem lesions).
Known, symptomatic leptomeningeal disease.
Have poorly controlled seizures.

What this trial measures

  • Number of Participants who experience a Dose-Limiting Toxicity (DLT)(Timeframe: up to 28 days)

    A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0). The number of participants who experience a DLT will be reported.

  • Number of participants with adverse events, treatment emergent adverse events or serious adverse events(Time Frame: 1 month post last dose of EIK1004 (IMP1707)

    Number of participants reporting adverse events or serious adverse events which include any abnormal clinical events, laboratory assessments outside of normal clinical range, abnormal vital signs observed, and any abnormal ECG parameters